ER与PR在钼靶X线假阴性乳腺癌中的表达及临床意义  

Expression and clinical significance of estrogen receptor and progesterone receptor of breast cancer with false-negative mammograms

作　　者：葛怀娥[1] 臧春霞[1] 李红文[1] 耿翠芝[2] 白希永[1] 崔海滨[1] 

机构地区：[1]河北省沧州市中心医院肿瘤外一科,061001 [2]河北医科大学第四医院外一科

出　　处：《河北医药》2009年第7期805-806,共2页Hebei Medical Journal

摘　　要：目的分析ER、PR在钼靶X线假阴性乳腺癌中表达的临床意义。方法将183例女性乳腺癌按照钼靶X线结果分成阳性和假阴性2组,采用免疫组化S-P法检测其ER、PR。结果钼靶X线假阴性组中,ER阳性比率低于阳性组(40%与67.57%,P=0.003);但2组患者PR阳性表达率差异无统计学意义(62.86%与57.43%,P=0.575)。结论与钼靶X线阳性患者相比,钼靶X线假阴性患者ER阳性表达率低,提示该组患者内分泌治疗效果及预后较差。Objective To analyzes the clinical significance of estrogen receptor （ER） and progesterone receptor （PR） expression in patients with false-negative mammograms. Methods 183 female patients with breast cancer identified by pathology were divided into two groups, positive group and false-negative group. The Streptavidin-peroxidase （SP） method（immunohistochemistry） was used to determine ER, PR of the patients. Results The ER positive rate in false-negative group was significantly lower than that of positive group （40% vs 67.57%, P 〈 0.01） ,however, there was no significant difference in PR positive rate between the two groups（62.86% vs 57.43%, P 〉 0.05）. Conclusion The positive expression rate of ER in breast cancer patients with false-negative mammograms is obviously lower than that of mammograms positive patients, which suggests that the patients have the worse therapeutic effect of endocrinotherapy and prognoses.

关 键 词：钼靶X线假阴性 免疫组化 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤] R814[医药卫生—临床医学]